Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19

Mostrar otras versiones (1)

BACKGROUND: Severe coronavirus disease 2019 (COVID-19) can manifest in rapid decompensation and respiratory failure with elevated inflammatory markers, consistent with cytokine release syndrome for which IL-6 blockade is an approved treatment. METHODS: We assessed effectiveness and safety of IL-6 bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Somers, Emily C, Eschenauer, Gregory A, Troost, Jonathan P, Golob, Jonathan L, Gandhi, Tejal N, Wang, Lu, Zhou, Nina, Petty, Lindsay A, Baang, Ji Hoon, Dillman, Nicholas O, Frame, David, Gregg, Kevin S, Kaul, Dan R, Nagel, Jerod, Patel, Twisha S, Zhou, Shiwei, Lauring, Adam S, Hanauer, David A, Martin, Emily, Sharma, Pratima, Fung, Christopher M, Pogue, Jason M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454462/
https://www.ncbi.nlm.nih.gov/pubmed/32651997
http://dx.doi.org/10.1093/cid/ciaa954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454462/
https://www.ncbi.nlm.nih.gov/pubmed/32651997
http://dx.doi.org/10.1093/cid/ciaa954

Ejemplares similares